DSM-Firmenich

Nutrition's good 'health'

18/11/20 -"We have factored in our more positive stance regarding DSM's future strategy in Nutrition, which goes much closer to the individual needs to stay healthy. This will lead to a higher profitability as ..."

PDF page sample
Pages
62
Language
English
Published on
18/11/20
Download
You may also be interested by these reports :
22/10/26
Yara’s Q3 2026 revenue growth was entirely price-driven. Higher gas costs outweighed price gains and squeezed earnings. Management responded with ...
21/10/26
AkzoNobel’s Q3 2026 sales were driven by pricing rather than demand: volumes fell again and full-year volume guidance was trimmed. Margins edged up ...
14/10/26
2026E: We raise our H2 2026 estimates, with our view that earnings will be driven primarily by pricing. We expect Q3 to broadly replicate Q2 2026, ...
13/10/26
Givaudan delivered a strong quarter, reaffirming its leading position in fragrances. Fine Fragrance continues to resist the normalisation anticipated ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO